[ad_1]
The Italian Medicines Agency ordered the removal of several batches of media based on the active substance valsartan. The decision was made because of some impurities that occurred during its production at the Zhejiang Huahai Pharmaceuticals plant, at the Chuannan site in China. The substance found is N-nitrosodimethylamine (Ndma), clbadified as potentially carcinogenic. Valsartan is an angiotensin II receptor antagonist and is used to treat hypertension and heart failure.
"In fact, a quality defect was discovered, therefore, as a precautionary measure, the AIFA and others The European agencies ordered the immediate withdrawal of pharmacies and the distribution chain of all relevant packaging, "says the agency on his website where he adds that" patients treated with valsartan should check if the drugs badume that they are on the list of people involved in precautionary withdrawal " , then indicating, still online, the list of products and lots concerned.
Source link
